ICER Proposes Legislative Mechanisms to Keep Prices Low for Drugs Receiving FDA’s Accelerated Approval Designation

The Institute for Clinical and Economic Review (ICER) suggests enacting federal legislation that would keep prices low for drugs receiving accelerated approval designation from the Food and Drug Administration (FDA). Such mechanisms could include price negotiation and tying price to patient outcomes.

“Congress should limit how much public and private insurers pay for drugs that get accelerated FDA approvals until drug companies prove those drugs work, the Institute for Clinical and Economic Review says, and ICER suggests policies for doing so. Those recommendations include mandating rebates, paying only production costs, creating a single price negotiator and payer for accelerated approval drugs and mandating outcomes-based contracts.” Read more here.

(Source: Gabrielle Wanneh, Inside Health Policy, 7/7/21)